LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Omeros Corp

Fechado

SetorSaúde

4.03 -1.23

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.02

Máximo

4.17

Indicadores-chave

By Trading Economics

Rendimento

8M

-25M

Margem de lucro

-8,121.359

Funcionários

202

EBITDA

9.3M

-26M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+120.05% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

8.6M

287M

Abertura anterior

5.26

Fecho anterior

4.03

Sentimento de Notícias

By Acuity

46%

54%

177 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Omeros Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de set. de 2025, 17:03 UTC

Grandes Movimentos do Mercado

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 de set. de 2025, 16:49 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

GD Culture Shares Drop After Deal for Pallas Capital

16 de set. de 2025, 16:11 UTC

Grandes Movimentos do Mercado

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 de set. de 2025, 23:40 UTC

Conversa de Mercado

Nikkei May Decline as Yen Strengthens -- Market Talk

16 de set. de 2025, 23:34 UTC

Conversa de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 de set. de 2025, 23:20 UTC

Conversa de Mercado

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 de set. de 2025, 21:10 UTC

Aquisições, Fusões, Aquisições de Empresas

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 de set. de 2025, 20:51 UTC

Conversa de Mercado

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 de set. de 2025, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

16 de set. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

16 de set. de 2025, 20:25 UTC

Ganhos

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 de set. de 2025, 20:24 UTC

Ganhos

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 de set. de 2025, 19:19 UTC

Conversa de Mercado

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 de set. de 2025, 18:52 UTC

Conversa de Mercado

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 de set. de 2025, 18:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

16 de set. de 2025, 18:44 UTC

Conversa de Mercado

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 de set. de 2025, 18:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 de set. de 2025, 18:38 UTC

Conversa de Mercado

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 de set. de 2025, 18:19 UTC

Conversa de Mercado

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 de set. de 2025, 18:01 UTC

Conversa de Mercado

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 de set. de 2025, 17:34 UTC

Conversa de Mercado

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 de set. de 2025, 16:53 UTC

Ganhos

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 de set. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

16 de set. de 2025, 16:15 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Commodities Roundup: Market Talk

16 de set. de 2025, 16:09 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Energy Roundup: Market Talk

16 de set. de 2025, 16:09 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 de set. de 2025, 15:35 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 de set. de 2025, 15:35 UTC

Conversa de Mercado

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 de set. de 2025, 15:22 UTC

Conversa de Mercado

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 de set. de 2025, 15:21 UTC

Conversa de Mercado

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparação entre Pares

Variação de preço

Omeros Corp Previsão

Preço-alvo

By TipRanks

120.05% parte superior

Previsão para 12 meses

Média 9 USD  120.05%

Máximo 9 USD

Mínimo 9 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Omeros Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

6.265 / 7.49Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

177 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat